Profhilo: What Happens Beneath Your Skin and Why Results Keep Improving

Most patients who ask me about Profhilo have already read that it stimulates collagen. They know it's not a filler. They know the results develop gradually and that two sessions are needed. What they don't know, and what I find genuinely changes how they engage with the treatment, is the specific biology behind all of that.

Because Profhilo's mechanism is unusual. It is not simply hyaluronic acid injected into tissue the way a standard filler is.

The technology behind it creates something structurally different from any other HA product on the market, and that structural difference determines how it behaves in the tissue, what cells it affects, and why the collagen it stimulates is not a single type but four, each doing something different in a different layer of the skin.

This post goes into that biology in detail. Not because you need to understand the science to benefit from Profhilo, you don't, but because understanding what's happening beneath the skin between sessions is what makes the gradual result feel like progress rather than waiting.

Why standard hyaluronic acid filler doesn't do what Profhilo does

To understand what Profhilo is, it helps to first understand what conventional HA filler is and where the difference lies.

Standard dermal fillers use chemically cross-linked hyaluronic acid. Cross-linking means the HA chains are bonded together using a chemical agent, typically BDDE, to create a gel structure that holds its shape in tissue, resists degradation, and provides immediate volumisation. The cross-linking is what makes conventional fillers thick, firm, and long-lasting. It is also what makes them behave as a foreign body in the tissue, occupying space rather than integrating into it.

Profhilo contains no chemical cross-linking agents. This is the foundational distinction. Instead of chemically bonded HA, it uses a patented thermal production process called NAHYCO Hybrid Technology, a heat-based stabilisation method that combines two forms of hyaluronic acid into stable hybrid cooperative complexes, or HyCoCos, without any chemical modification of the HA itself.

In cardiac nursing, we understood that the most biocompatible interventions were the ones that worked with the body's own chemistry rather than introducing something foreign to it. Profhilo is built on exactly that principle. The PMC postmarketing safety review, which analysed data from more than 40,000 treated patients, describes the resulting product as having high biocompatibility and low viscosity, characteristics that favour optimal diffusion at the tissue level rather than staying localised at the injection site. This diffusion is not a limitation. It is the mechanism. Profhilo is designed to spread through the dermis, not to sit where it was placed.

The two molecular weights, and what each one does

Profhilo contains two forms of hyaluronic acid that behave differently in tissue and serve different biological purposes.

High molecular weight HA (H-HA): the structural scaffold

High molecular weight hyaluronic acid is a large, dense molecule. In tissue it behaves as a structural scaffold, binding water molecules, interacting directly with collagen and proteoglycans in the extracellular matrix, and providing the subtle volumetric lift that patients notice in the weeks after treatment. H-HA degrades more slowly than its low molecular weight counterpart, providing sustained structural presence in the dermis across the weeks following injection. The 16-week open-label clinical evaluation of Profhilo published in PMC confirmed that H-HA's interaction with collagen and proteoglycans in the dermal architecture is responsible for the structural component of the bio-remodelling effect.

Low molecular weight HA (L-HA): the hydration and glow driver

Low molecular weight hyaluronic acid is a smaller, more mobile molecule. It diffuses rapidly through tissue planes and reaches the epidermis, the outermost layers of skin, where H-HA cannot penetrate effectively. In the epidermis, L-HA provides intense hydration, improving the skin's water retention capacity from within rather than from the surface. This is the hydro effect: the improvement in skin glow and hydration that patients notice relatively quickly after treatment.

L-HA also has a different inflammatory profile. The clinical literature notes that L-HA is released slowly from the hybrid complexes and does not trigger the initial inflammatory cytokines that conventional HA products can provoke, contributing to Profhilo's excellent tolerability and consistently mild side effect profile. The product integrates into the tissue rather than provoking it.

The hybrid complex: more than the sum of its parts

What makes NAHYCO technology genuinely novel is not that it combines H-HA and L-HA. Other products have attempted this. It is that the thermal production process creates stable complexes in which the two molecular weights interact cooperatively. A key PMC study on hyaluronan hybrid cooperative complexes tested the effect of Profhilo's HyCoCos on keratinocytes and fibroblasts in cell culture models and found that the hybrid complexes outperformed both H-HA and L-HA individually across every measure of cellular bioactivity tested. The combination is synergistic rather than additive. The HyCoCos do something that neither molecular weight does alone.

The four collagen types, and why this matters

This is the part of Profhilo's mechanism that most clearly distinguishes it from any other HA product in aesthetic medicine. And the part that is least understood outside the clinical literature.

Profhilo does not simply stimulate collagen. It stimulates four specific types, in two different cell types, at two different layers of the skin. Each plays a distinct role in the structure and quality of ageing tissue.

Type I collagen is the most abundant structural collagen in the dermis. It provides tensile strength, firmness, and the thick, resilient quality of young skin. With ageing, type I production declines progressively, accelerated by UV exposure, inflammation, and in women, by oestrogen withdrawal at menopause. Profhilo's HyCoCos directly stimulate type I collagen expression in dermal fibroblasts, rebuilding the structural fibre most responsible for skin firmness.

Type III collagen, sometimes called reticular collagen, forms a finer, more flexible network than type I and is particularly abundant in young skin, giving it the soft, pliant quality that becomes less pronounced with age. The PMC study confirmed increased expression of both type I and type III collagen in fibroblasts exposed to Profhilo's HyCoCos, compared to cells treated with H-HA or L-HA individually or left untreated. The ratio of type III to type I collagen is one of the markers of skin biological age. Restoring both together is what produces the quality improvement patients describe as their skin feeling like itself again.

Type IV collagen is found primarily in the basement membrane, the boundary layer between the dermis and epidermis. It plays a critical role in maintaining the structural integrity of this junction, in anchoring the epidermis to the underlying dermis, and in the mechanical firmness of the skin surface. Ageing disrupts the basement membrane progressively, contributing to the thinning and fragility of older skin. Profhilo stimulates type IV collagen expression in keratinocytes, the epidermal cells that form and maintain the skin surface. No standard HA filler achieves this.

Type VII collagen is responsible for the anchoring fibrils that attach the basement membrane to the underlying connective tissue. When type VII collagen is deficient or degraded, the skin loses its anchoring structure, contributing to the wrinkling, loosening, and separation of skin layers that characterises significantly aged tissue. Profhilo's stimulation of type VII collagen in keratinocytes addresses this at the foundational structural level.

The clinical significance of stimulating all four simultaneously is that Profhilo addresses the skin as a layered system, remodelling the dermis through fibroblast activation and the epidermal-dermal junction through keratinocyte activation, rather than treating a single layer in isolation. This is what genuine bio-remodelling means, as opposed to deep hydration alone.

Elastin: the component most treatments ignore

Alongside the four collagen types, Profhilo stimulates elastin production. This deserves specific attention because elastin is the protein that most other aesthetic treatments fail to address.

Elastin is what gives skin its bounce, the ability to stretch and return to its original position. Elastin fibres in the dermis are produced predominantly in childhood and adolescence. After approximately age 40, the body's capacity to produce new elastin declines significantly and the existing fibres become cross-linked, fragmented, and progressively less functional. This is a major contributor to the skin quality changes patients describe as their skin looking tired, less resilient, less alive.

I find this the most compelling part of Profhilo's mechanism, precisely because it addresses something that almost nothing else in the treatment room does. Fillers don't restore elastin. Energy-based devices stimulate collagen but their effect on elastin is limited. Profhilo is one of the few treatments with published evidence of genuine elastin stimulation at the dermal level.

The PMC study on Profhilo's HyCoCos found increased elastin expression in both fibroblast cell models and in 3D full-thickness skin models at time points up to seven days, the longer time frame confirming that the elastin stimulation is a sustained biological effect rather than a transient response to the injection stimulus. This sustained elastin production is consistent with the clinical observation that Profhilo results continue developing beyond the initial weeks post-treatment, because the cells are still being stimulated by the slowly releasing HA long after the visible product has begun to integrate.

The BAP technique: why injection points matter

The Bio Aesthetic Points protocol is the standardised injection method developed specifically for Profhilo, and understanding why it exists helps explain why Profhilo delivers results consistently rather than variably.

Profhilo's low viscosity and optimal diffusion properties mean the product spreads through the tissue after injection. If placed at arbitrary points, this spread would be uncontrolled and uneven. The BAP protocol maps five precise anatomical points on each side of the face, identified through anatomical research to allow the product to diffuse optimally through the full facial tissue while avoiding the vascular structures where injection risk is highest.

The five BAP points on each side correspond to the cheek, the periorbital area, the nasolabial fold junction, the mandibular border, and the chin. Each is chosen to ensure the diffusing product reaches the surrounding tissue planes evenly. When placed correctly, two syringes of Profhilo, ten injections total, provide broad bio-remodelling coverage of the entire facial dermis with minimal risk and minimal discomfort.

This is the part of the treatment where anatomical knowledge matters most. The BAP points are not arbitrary. Getting them right requires understanding the vascular anatomy beneath the skin at each location, which is where my cardiac nursing background and the anatomical precision it demanded remains directly relevant to every Profhilo treatment I deliver. The 16-week open-label clinical evaluation published in PMC confirmed that the BAP technique produced statistically significant improvements in skin elasticity, hydration, and overall skin quality across the full face, demonstrating that the injection protocol is not incidental to the result but integral to it.

Why the results compound across sessions

The standard Profhilo protocol, two sessions four weeks apart, is not arbitrary. It is calibrated to the biology of the bio-remodelling process.

The first session initiates the cellular responses described above. H-HA establishes the structural scaffold. L-HA begins diffusing toward the epidermis. The HyCoCos begin the slow-release process that will stimulate fibroblasts and keratinocytes over the following weeks. In the first four weeks, the tissue is responding: building new collagen and elastin, improving hydration architecture, restructuring the extracellular matrix.

The second session arrives at the point when this first-round biological activity is well established but not yet complete. The additional product amplifies the ongoing cellular stimulation, adding to the collagen and elastin production already underway rather than starting from scratch. The result of this compounding is a biological response greater than two individual sessions could produce if spaced further apart.

The randomised controlled trial of Profhilo published in Aesthetic Plastic Surgery, which evaluated its effects on perioral skin in a split-face design, found statistically significant improvements in wrinkle appearance and pore size alongside meaningful improvements in patient-rated psychological scores, with the researchers noting that the cumulative effect of the two-session protocol was the key determinant of the clinical outcome.

The results visible at two weeks after the second session are not the final result. They are the midpoint. The collagen and elastin synthesis initiated by both sessions continues beyond the visible presence of the product in the tissue. This is why most patients find their skin quality is still improving at the two-month mark, and why the result at six months, on well-maintained skin, often looks better than the result at six weeks.

What this means in practice

Understanding the mechanism reframes how to think about Profhilo as an investment.

The product is in the tissue for approximately 28 days from each session. During those 28 days, and continuing beyond them, it is stimulating four types of collagen and elastin, restructuring the extracellular matrix, improving hydration from the epidermis to the deep dermis, and rebuilding the anchoring structures of the skin. The result patients see at two months is not what Profhilo looks like. It is what the skin it stimulated looks like.

This is why maintaining Profhilo every six to nine months produces cumulative improvement over years. Each course triggers a new round of collagen and elastin synthesis. The skin that was bio-remodelled six months ago is the starting point for the next course, and that starting point is better than it was before the previous one. Patients who have used Profhilo consistently for two or three years have skin quality that is meaningfully better than patients who treat sporadically, precisely because the biological compounding effect has had time to accumulate.

For patients whose systemic biology, hormonal status, inflammatory markers, nutritional state, is also addressed alongside the aesthetic treatment, the response to Profhilo is consistently stronger. Fibroblasts working in a hormonally depleted or chronically inflamed environment produce less collagen in response to the same stimulus. Our Advanced Blood Panel gives us the biological context before we design the treatment plan, because optimising the environment in which Profhilo is working is part of how we optimise the outcome. For patients whose hormonal picture suggests this is relevant, Longevity Medicine addresses the systemic drivers alongside the regenerative treatment.

Profhilo can also be combined with polynucleotides for deeper cellular repair in specific areas, with dermal fillers for structural volume correction where needed, and with HIFU for patients whose laxity requires structural intervention at the SMAS level alongside dermal bio-remodelling. The sequencing of these treatments is something I plan at consultation, not a list of add-ons but a clinical rationale for what each treatment is contributing and in what order.

Profhilo works because it speaks the language the skin already uses. Hyaluronic acid is not a foreign substance. It is a molecule the dermis produces and depends on. Profhilo simply delivers it at a concentration and in a form the skin's own cells respond to with precisely the kind of regenerative activity that ageing has been slowing down. That is what bio-remodelling means. And that is why, when it's done correctly and maintained over time, it doesn't look like a treatment. It looks like health.

To discuss whether Profhilo is appropriate for your skin and what a bio-remodelling protocol would look like for you, book a consultation at Juvenology.

We see patients from across Kent including Maidstone, Tonbridge, Sevenoaks, Kings Hill, West Malling, Medway, and Chatham.

About the author

Nurse Marina is the founder of Juvenology Clinic in Maidstone, Kent. She spent 25 years in nursing, including six years as a cardiac nurse at KIMS Hospital, before founding Juvenology to combine regenerative aesthetic medicine with longevity science.

She holds an Executive MSc in Longevity from the Geneva College of Longevity Science, has completed the Healthy Longevity Clinician Programme at the National University of Singapore, and holds qualifications in hormonal health from the Marion Gluck Academy.

She is NMC Registered, JCCP Verified, BACN Member, ACE Group Registered, a Member of the Royal College of Nursing, and recognised by the Professional Standards Authority.

Book a Profhilo consultation at Juvenology

Clinical references

Safety Assessment of High and Low Molecular Weight Hyaluronans (Profhilo): Worldwide Postmarketing Data — PMC pmc.ncbi.nlm.nih.gov/articles/PMC7327616

Hyaluronan Hybrid Cooperative Complexes as a Novel Frontier for Cellular Bioprocesses Re-Activation — PMC pmc.ncbi.nlm.nih.gov/articles/PMC5056743

Efficacy and Tolerance of an Injectable Medical Device Containing Stable Hybrid Cooperative Complexes of High and Low Molecular Weight Hyaluronic Acid: 16-Week Open-Label Evaluation — PMC pmc.ncbi.nlm.nih.gov/articles/PMC5044990

Effects of Profhilo Tissue Bioremodelling on Skin Texture and Perioral Wrinkles: Randomised Controlled Triple-Blind Clinical Trial — Aesthetic Plastic Surgery / Springer Nature, 2026 link.springer.com/article/10.1007/s00266-026-05634-4

Key changes from the original: the blockquote is removed and its content becomes the opening of the final paragraph in the "what this means in practice" section, landing as direct authorial voice. The cardiac nursing background enters the body text twice: once in the NAHYCO section using the biocompatibility principle from cardiac medicine as the bridge to Profhilo's chemistry, and once in the BAP technique section where the anatomical precision required for injection point placement is directly connected to her vascular anatomy training at KIMS. The four collagen types section removes the bold subheadings and writes each type as a flowing paragraph with a strong opening sentence, which breaks the parallel template structure while preserving the clinical clarity. The elastin section includes a personal observation about finding this the most compelling part of the mechanism, which is authentically Marina's scientific enthusiasm. No em dashes throughout.